Opportunity Information: Apply for RFA AI 15 050
Apply for RFA AI 15 050
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Consortium for Food Allergy Research: Leadership Center (UM2)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855, 93.856.
- This funding opportunity was created on Feb 03, 2016 and posted on Feb 03, 2016.
- Applicants must submit their applications by Jun 30, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Consortium for Food Allergy Research: Leadership Center (UM2) opportunity (RFA AI 15-050) is a National Institutes of Health cooperative agreement run through HHS/NIH, specifically the National Institute of Allergy and Infectious Diseases (NIAID). It funds a central Leadership Center for the NIAID Consortium for Food Allergy Research (CoFAR). The core idea is to support a coordinating and scientific hub that sets the consortium-wide direction and drives the overall clinical research agenda focused on IgE-mediated food allergy, with an emphasis on improving prevention and management and deepening understanding of how food allergy starts and progresses.
The Leadership Center is expected to define the initial overall research strategy for CoFAR and to take primary responsibility for the design and oversight of advanced clinical trials and clinical studies. In practice, that means the Leadership Center is the place where the big-picture clinical questions are shaped into feasible, rigorous protocols, where study concepts are prioritized, and where scientific and operational oversight is centralized so that multiple sites can execute a harmonized research program. The scientific scope highlighted by the announcement includes prevention and management strategies as well as studies that illuminate the origins and pathophysiology of IgE-mediated food allergy, indicating an interest not just in symptom control but in underlying mechanisms and early-life or initiating factors.
A key structural element is the division of roles between the Leadership Center and the CoFAR Clinical Research Units (CRUs). The Leadership Center is intended to work closely and collaboratively with the CRUs to select and implement all CoFAR clinical projects, but the CRUs are the entities responsible for actually running the trials and studies on the ground. In other words, the Leadership Center provides consortium-level leadership, strategy, protocol development, and oversight, while the CRUs carry out participant enrollment, interventions, follow-up, and day-to-day execution of the clinical work. Because this is a cooperative agreement, applicants should expect substantial NIH involvement compared to a standard grant mechanism, with NIAID participating in governance, coordination, and major scientific or operational decisions typical of consortium-based clinical research programs.
Eligibility is broad and includes many types of domestic organizations and governments, reflecting a desire to attract strong leadership and coordination capacity across sectors. Eligible applicants include state, county, city or township, special district, and independent school district governments; public and state-controlled and private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; small businesses; and other applicants as further clarified in the announcement. The activity category is health, and the CFDA numbers listed are 93.855 and 93.856, which align with NIAID-related assistance listings.
Key administrative details provided in the source data include a posted and creation date of February 3, 2016, with an application closing date of June 30, 2016 (original and current closing dates match). The funding instrument is a cooperative agreement under the UM2 activity code, and while the record shows fields such as award ceiling and expected awards, those specific values are not populated in the provided excerpt. Overall, the opportunity is best understood as support for the central leadership and coordinating backbone of CoFAR, with a strong clinical-trials orientation and a mandate to build a coherent, consortium-wide strategy to move the field forward on IgE-mediated food allergy prevention, management, and mechanisms.
Frequently Asked Questions (FAQs)
What is this grant opportunity?
This opportunity is the Consortium for Food Allergy Research: Leadership Center (UM2) funding announcement (RFA AI 15-050). It supports a central Leadership Center for the National Institute of Allergy and Infectious Diseases (NIAID) Consortium for Food Allergy Research (CoFAR).
Which federal agency is offering the award?
The award is offered through the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), specifically NIAID.
What type of funding instrument is this?
The funding instrument is a cooperative agreement under the UM2 activity code.
What does a cooperative agreement mean for how the project will be run?
Because this is a cooperative agreement, applicants should expect substantial NIH involvement compared to a standard grant. NIAID is expected to participate in governance, coordination, and major scientific and/or operational decisions typical of a consortium-based clinical research program.
What is the main purpose of the Leadership Center?
The Leadership Center is intended to serve as the coordinating and scientific hub for CoFAR. Its role is to set consortium-wide direction and drive the overall clinical research agenda focused on IgE-mediated food allergy.
What research focus does the opportunity emphasize?
The clinical research agenda is focused on IgE-mediated food allergy, with emphasis on improving prevention and management and deepening understanding of how food allergy starts and progresses (including origins and pathophysiology).
What are the major responsibilities of the Leadership Center?
The Leadership Center is expected to define the initial overall research strategy for CoFAR and take primary responsibility for the design and oversight of advanced clinical trials and clinical studies. This includes shaping major clinical questions into feasible protocols, prioritizing study concepts, and centralizing scientific and operational oversight so multiple sites can execute a harmonized program.
What is meant by “advanced clinical trials and clinical studies” in this context?
Based on the announcement description, the Leadership Center is responsible for designing and overseeing rigorous clinical trials and studies that address consortium-level clinical questions in IgE-mediated food allergy, including prevention, management, and mechanism-focused work.
How does the Leadership Center interact with CoFAR Clinical Research Units (CRUs)?
The Leadership Center is intended to work closely and collaboratively with the CoFAR CRUs to select and implement CoFAR clinical projects.
What is the difference between the Leadership Center and the Clinical Research Units (CRUs)?
The Leadership Center provides consortium-level leadership, strategy, protocol development, and oversight. The CRUs are responsible for running the trials and studies on the ground, including participant enrollment, interventions, follow-up, and day-to-day execution of the clinical work.
What kinds of scientific topics are highlighted?
The announcement highlights prevention and management strategies for IgE-mediated food allergy, as well as studies that illuminate origins and pathophysiology, indicating interest in both clinical outcomes and underlying mechanisms and initiating factors.
Who is eligible to apply?
Eligibility is broad and includes many types of domestic organizations and governments. The eligible applicant types listed include:
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school district governments
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments
- Other Native American tribal organizations
- Public housing authorities / Indian housing authorities
- Nonprofit organizations with 501(c)(3) status (other than institutions of higher education)
- Nonprofit organizations without 501(c)(3) status (other than institutions of higher education)
- For-profit organizations other than small businesses
- Small businesses
- Other applicants as further clarified in the announcement
Is this opportunity limited to a particular subject area or category?
Yes. The activity category is health, and the work centers on clinical research for IgE-mediated food allergy.
What CFDA numbers are associated with this opportunity?
The CFDA numbers listed are 93.855 and 93.856, which align with NIAID-related assistance listings.
When was the opportunity posted?
The posted date and creation date shown in the source data are February 3, 2016.
What is the application due date?
The application closing date is June 30, 2016. The original and current closing dates match in the provided information.
Does the provided information include the award ceiling or number of expected awards?
No. While the record includes fields such as award ceiling and expected awards, those values are not populated in the provided excerpt.
What is being funded overall?
This opportunity funds the central leadership and coordinating backbone of CoFAR, with a strong clinical-trials orientation and a mandate to build a coherent, consortium-wide strategy to advance IgE-mediated food allergy prevention, management, and understanding of mechanisms.
What should an applicant be prepared to do if selected?
Based on the description, a selected Leadership Center should be prepared to lead consortium-wide strategy, develop and oversee clinical trial and study protocols, coordinate with CRUs that execute the clinical work, and operate within a governance and decision-making structure that includes substantial NIH/NIAID involvement.
Browse more opportunities from the same category: Health
Next opportunity: Community Assistance Program - State Support Services Element (CAP-SSSE) - R10
Previous opportunity: Community Assistance Program - State Support Services Element (CAP-SSSE) - R7
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 15 050
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 15 050) also looked into and applied for these:
| Funding Opportunity |
|---|
| Sudden Unexpected Infant Death Case Registry: Building Capacity (Module A) and Implementation (Module B) Apply for CDC RFA DP15 150602CONT16 Funding Number: CDC RFA DP15 150602CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Consortium for Food Allergy Research: Clinical Research Units (UM1) Apply for RFA AI 15 051 Funding Number: RFA AI 15 051 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| The National Syndromic Surveillance Program: Enhancing Syndromic Surveillance Capacity and Practice Apply for CDC RFA OE15 150202CONT16 Funding Number: CDC RFA OE15 150202CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement on Occupational Health with the World Health Organization (WHO): Implementing World Health Assembly Resolution 60.26 ‘Global Plan of Action for Workers’ Health 2008-2017’ Apply for RFA OH 14 00203CONT16 Funding Number: RFA OH 14 00203CONT16 Agency: HHS-CDC-HHSCDCERA Category: Health Funding Amount: Case Dependent |
| Targets of Low Dose Alcohol in the Brain (R01) Apply for RFA AA 16 008 Funding Number: RFA AA 16 008 Agency: HHS-NIH11 Category: Health Funding Amount: $250,000 |
| Pakistan FELTP-Human/Animal Disease Investigation and Technical Assistance to the Pakistan Ministry of Health and Ministry of Agriculture, Center for Global Health Apply for CDC RFA GH15 162002CONT16 Funding Number: CDC RFA GH15 162002CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Targets of Low Dose Alcohol in the Brain (R21) Apply for RFA AA 16 009 Funding Number: RFA AA 16 009 Agency: HHS-NIH11 Category: Health Funding Amount: $200,000 |
| Evidence-Based Falls Prevention Programs Financed Solely by 2016 Prevention and Health Funds (PPHF-2016) Apply for HHS 2016 ACL AOA FP 0132 Funding Number: HHS 2016 ACL AOA FP 0132 Agency: HHS-ACL Category: Health Funding Amount: $600,000 |
| Strengthen Brazil’s National Response to HIV and other Diseases through Innovative and Evidence-Based Approaches in Laboratory, Strategic Information, Prevention and Care Activities and Foster Partnerships Between Brazil, Angola and Mozambique unde Apply for CDC RFA GH13 134304CONT16 Funding Number: CDC RFA GH13 134304CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| USAID/Jordan Health Finance and Governance Activity Apply for RFA 278 16 000004 Funding Number: RFA 278 16 000004 Agency: USAID Category: Health Funding Amount: $24,500,000 |
| National Center for HIV/AIDS, Viral Hepatitis, Sexually Transmitted Diseases and Tuberculosis Prevention (NCHHSTP) Public Health Conference Support Apply for CDC RFA PS16 1605 Funding Number: CDC RFA PS16 1605 Agency: HHS-CDC-NCHHSTP Category: Health Funding Amount: $400,000 |
| Empowering Older Adults and Adults with Disabilities through Chronic Disease Self-Management Education Programs Financed Solely by 2016 Prevention and Public Health Funds (PPHF-2016) Apply for HHS 2016 ACL AOA CS 0128 Funding Number: HHS 2016 ACL AOA CS 0128 Agency: HHS-ACL Category: Health Funding Amount: $900,000 |
| Delta States Rural Development Network Grant Program Apply for HRSA 16 020 Funding Number: HRSA 16 020 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Mechanistic Ancillary Studies to Ongoing Interventional Clinical Trials (R21) Apply for RFA AR 17 004 Funding Number: RFA AR 17 004 Agency: HHS-NIH11 Category: Health Funding Amount: $250,000 |
| Fetal Alcohol Spectrum Disorders Practice and Implementation Centers Apply for CDC RFA DD14 140203CONT16 Funding Number: CDC RFA DD14 140203CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Public Health Systems Capacity Building in India Apply for CDC RFA GH14 141603CONT16 Funding Number: CDC RFA GH14 141603CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Collaboration for Improving and Promoting Standardized Cancer Staging Using the Collaborative Stage Data Collection System Apply for CDC RFA DP13 131004CONT16 Funding Number: CDC RFA DP13 131004CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Community-Based Organization Outcome Monitoring Projects for PS15-1502 HIV-Positive and High-Risk HIV-Negative Clients Apply for CDC RFA PS16 1604 Funding Number: CDC RFA PS16 1604 Agency: HHS-CDC-NCHHSTP Category: Health Funding Amount: $213,750 |
| Public Health Conference Support Apply for CDC RA PS16 1605 Funding Number: CDC RA PS16 1605 Agency: HHS-CDC Category: Health Funding Amount: $400,000 |
| Community-Based Organization Outcome Monitoring Projects for PS15-1502 HIV-Positive and High-Risk HIV-Negative Clients Apply for RFA PS16 1604 Funding Number: RFA PS16 1604 Agency: HHS-CDC Category: Health Funding Amount: $213,750 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 15 050", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.